Molecular networking for drug toxicities studies: The case of hydroxychloroquine in covid-19 patients - Ischémie Reperfusion en Transplantation d’Organes Mécanismes et Innovations Thérapeutiques Accéder directement au contenu
Article Dans Une Revue International Journal of Molecular Sciences Année : 2022

Molecular networking for drug toxicities studies: The case of hydroxychloroquine in covid-19 patients

Résumé

Using drugs to treat COVID-19 symptoms may induce adverse effects and modify patient outcomes. These adverse events may be further aggravated in obese patients, who often present different illnesses such as metabolic-associated fatty liver disease. In Rennes University Hospital, several drug such as hydroxychloroquine (HCQ) have been used in the clinical trial HARMONICOV to treat COVID-19 patients, including obese patients. The aim of this study is to determine whether HCQ metabolism and hepatotoxicity are worsened in obese patients using an in vivo/in vitro approach. Liquid chromatography high resolution mass spectrometry in combination with untargeted screening and molecular networking were employed to study drug metabolism in vivo (patient’s plasma) and in vitro (HepaRG cells and RPTEC cells). In addition, HepaRG cells model were used to reproduce pathophysiological features of obese patient metabolism, i.e., in the condition of hepatic steatosis. The metabolic signature of HCQ was modified in HepaRG cells cultured under a steatosis condition and a new metabolite was detected (carboxychloroquine). The RPTEC model was found to produce only one metabolite. A higher cytotoxicity of HCQ was observed in HepaRG cells exposed to exogenous fatty acids, while neutral lipid accumulation (steatosis) was further enhanced in these cells. These in vitro data were compared with the biological parameters of 17 COVID-19 patients treated with HCQ included in the HARMONICOV cohort. Overall, our data suggest that steatosis may be a risk factor for altered drug metabolism and possibly toxicity of HCQ. © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
Fichier principal
Vignette du fichier
ijms-23-00082-v2.pdf (3.05 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03515202 , version 1 (06-05-2022)

Licence

Paternité

Identifiants

Citer

P.-J. Ferron, B. Le Daré, J. Bronsard, C. Steichen, E. Babina, et al.. Molecular networking for drug toxicities studies: The case of hydroxychloroquine in covid-19 patients. International Journal of Molecular Sciences, 2022, 23 (1), pp.82. ⟨10.3390/ijms23010082⟩. ⟨hal-03515202⟩
152 Consultations
33 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More